NASDAQ: FENCFennec Pharmaceuticals Inc Stock
$4.62+0.10 (+2.21%)
Updated Oct 4, 2024
FENC Price
$4.62
Fair Value Price
-$3.62
Market Cap
$126.42M
52 Week Low
$4.50
52 Week High
$11.92
P/E
46.2x
P/B
-93.16x
P/S
3.41x
PEG
0.4x
Dividend Yield
N/A
Revenue
$48.89M
Earnings
$3.64M
Gross Margin
95.6%
Operating Margin
15.32%
Profit Margin
7.4%
Debt to Equity
-47.55
Operating Cash Flow
$23M
Beta
0.74
Next Earnings
Nov 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FENC Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FENC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FENC ($4.62) is overvalued by 227.76% relative to our estimate of its Fair Value price of -$3.62 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FENC ($4.62) is not significantly undervalued (227.76%) relative to our estimate of its Fair Value price of -$3.62 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FENC ($4.62) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FENC due diligence checks available for Premium users.
Be the first to know about important FENC news, forecast changes, insider trades & much more!
FENC News
Valuation
FENC fair value
Fair Value of FENC stock based on Discounted Cash Flow (DCF)
Price
$4.62
Fair Value
-$3.62
Undervalued by
227.76%
FENC ($4.62) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FENC ($4.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FENC ($4.62) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FENC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
46.2x
Industry
-113.8x
Market
26.83x
FENC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
FENC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
FENC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-93.16x
Industry
5.96x
FENC price to earnings growth (PEG)
For valuing profitable companies with growth potential
FENC is good value based... subscribe to Premium to read more.
PEG Value Valuation
FENC's financial health
Profit margin
Revenue
$7.3M
Net Income
-$5.6M
Profit Margin
-76.5%
FENC's Earnings (EBIT) of $7.49M... subscribe to Premium to read more.
Interest Coverage Financials
FENC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.2M
Liabilities
$64.5M
Debt to equity
-47.55
FENC's short-term assets ($62.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FENC's short-term assets ($62.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FENC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FENC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.4M
Investing
$0.0
Financing
$257.0k
FENC's operating cash flow ($23.04M)... subscribe to Premium to read more.
Debt Coverage Financials
FENC vs Biotech Stocks
Fennec Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.